Fast Five Quiz: Next-Generation Sequencing in Non–Small Cell Lung Cancer

Maurie Markman, MD

Disclosures

August 22, 2022

Nearly 30% of NSCLC harbor a mutation in the KRAS oncogene, making KRAS the most common oncogenic driver in lung cancer. The prevalence of mutations in the EGFR oncogenes overall is 19%, although it is much higher among Asian patients with lung adenocarcinoma. BRAF mutations occur in about 5% of patients. NTRK is rare, occurring in < 1% of patients.

Learn more about oncogenic driver mutations in NSCLC.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....